Literature DB >> 25361800

Solid malignancies in individuals with Down syndrome: a case presentation and literature review.

Scott V Bratman1, Kathleen C Horst1, Robert W Carlson2, Daniel S Kapp1.   

Abstract

Individuals with Down syndrome (DS) are at elevated risk for acute leukemia, whereas solid tumors are uncommon, and most types, including breast cancers, have significantly lower-than-expected age-adjusted incidence rates. This article reports on a man with DS and breast cancer, thought to be the first in the literature, and presents the management of his cancer. The literature on malignancies in patients with DS is reviewed and the major epidemiologic studies that have examined the spectrum of cancer risk in individuals with DS are summarized. Potential environmental and genetic determinants of cancer risk are discussed, and the potential role of chromosomal mosaicism in cancer risk among patients with DS is explored. Trisomy of chromosome 21, which causes DS, provides an extra copy of genes with tumor suppressor or repressor functions. Recent studies have leveraged mouse and human genetics to uncover specific candidate genes on chromosome 21 that mediate these effects. In addition, global perturbations in gene expression programs have been observed, with potential effects on proliferation and self-renewal.
Copyright © 2014 by the National Comprehensive Cancer Network.

Entities:  

Mesh:

Year:  2014        PMID: 25361800     DOI: 10.6004/jnccn.2014.0153

Source DB:  PubMed          Journal:  J Natl Compr Canc Netw        ISSN: 1540-1405            Impact factor:   11.908


  4 in total

1.  Trisomy 21 consistently activates the interferon response.

Authors:  Kelly D Sullivan; Hannah C Lewis; Amanda A Hill; Ahwan Pandey; Leisa P Jackson; Joseph M Cabral; Keith P Smith; L Alexander Liggett; Eliana B Gomez; Matthew D Galbraith; James DeGregori; Joaquín M Espinosa
Journal:  Elife       Date:  2016-07-29       Impact factor: 8.140

Review 2.  Trans-acting epigenetic effects of chromosomal aneuploidies: lessons from Down syndrome and mouse models.

Authors:  Catherine Do; Zhuo Xing; Y Eugene Yu; Benjamin Tycko
Journal:  Epigenomics       Date:  2016-12-02       Impact factor: 4.778

3.  Rapamycin Treatment Ameliorates Age-Related Accumulation of Toxic Metabolic Intermediates in Brains of the Ts65Dn Mouse Model of Down Syndrome and Aging.

Authors:  Nathan Duval; Guido N Vacano; David Patterson
Journal:  Front Aging Neurosci       Date:  2018-09-06       Impact factor: 5.750

4.  Down syndrome iPSC model: endothelial perspective on tumor development.

Authors:  Mariana Perepitchka; Yekaterina Galat; Igor P Beletsky; Philip M Iannaccone; Vasiliy Galat
Journal:  Oncotarget       Date:  2020-09-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.